American Society of Hirudotherapy

Heparin-induced thrombocytopenia: real-world issues

Research article published in Seminars in thrombosis and hemostasis (2011)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsLinkins LA et al. · Seminars in thrombosis and hemostasis, 2011

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic drug reaction caused by platelet-activating antibodies. HIT sera often activate platelets without needing heparin-such heparin-"independent" platelet activation can be associated with HIT beginning or worsening despite stopping heparin ("delayed-onset HIT"). We address important issues in HIT diagnosis and therapy, using a recent cohort of HIT patients to illustrate influences of heparin type; triggers for HIT investigation; serological features of heparin-independent platelet activation; and treatment. In our cohort of recent HIT cases ( N = 13), low-molecular-weight heparin (dalteparin) was a common causative agent ( N = 8, 62%); most patients were diagnosed after HIT-thrombosis had occurred; and danaparoid was the most frequently selected treatment. Heparin-independent platelet activation was common (7/13 [54%]) and predicted slower platelet count recovery (>1 week) among evaluable patients (5/5 vs 1/6; P = 0.015). In our experience with argatroban-treated patients, HIT-associated consumptive coagulopathy confounds anticoagulant monitoring. Our observations provide guidance on practical aspects of HIT diagnosis and management.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAgedAged, 80 and overAnticoagulantsFemaleHeparinHeparin, Low-Molecular-WeightHumansMaleMiddle AgedNeoplasmsOrthopedic ProceduresPlatelet Count

Summary

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Why This Matters for Hirudotherapy

This article addresses real-world diagnosis and treatment of heparin-induced thrombocytopenia (HIT), using a small recent case cohort (N=13) to illustrate practical issues; the abstract reports that low-molecular-weight heparin (dalteparin) was a common trigger (8/13, 62%), that heparin-independent platelet activation was common (7/13, 54%) and predicted slower platelet-count recovery (5/5 vs 1/6; P=0.015), and that danaparoid and argatroban were used as alternative anticoagulants. Its relevance to hirudotherapy is again the non-heparin-anticoagulant theme: HIT forces clinicians toward direct thrombin inhibitors, the mechanistic family pioneered by the leech protein hirudin, which keeps the medicinal-leech secretome connected to mainstream coagulation pharmacology. The caveat is that this is a small single-center cohort/case series offered as illustrative practical guidance, not a powered trial, and it evaluates synthetic alternative anticoagulants rather than any leech-based therapy.

Citation

Heparin-induced thrombocytopenia: real-world issues.

Linkins LA et al. · Seminars in thrombosis and hemostasis, 2011

DOI

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.